Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration.
Probst, G.D., Bowers, S., Sealy, J.M., Truong, A.P., Hom, R.K., Galemmo, R.A., Konradi, A.W., Sham, H.L., Quincy, D.A., Pan, H., Yao, N., Lin, M., Toth, G., Artis, D.R., Zmolek, W., Wong, K., Qin, A., Lorentzen, C., Nakamura, D.F., Quinn, K.P., Sauer, J.M., Powell, K., Ruslim, L., Wright, S., Chereau, D., Ren, Z., Anderson, J.P., Bard, F., Yednock, T.A., Griswold-Prenner, I.(2011) Bioorg Med Chem Lett 21: 315-319
- PubMed: 21112785 
- DOI: 10.1016/j.bmcl.2010.11.010
- Primary Citation of Related Structures:  
3OY1 - PubMed Abstract: 
In this Letter, we describe the discovery of selective JNK2 and JNK3 inhibitors, such as 10, that routinely exhibit >10-fold selectivity over JNK1 and >1000-fold selectivity over related MAPKs, p38α and ERK2. Substitution of the naphthalene ring affords ...